M

Seres Therapeutics
D

MCRB

0.69250
USD
0.01
(1.60%)
مغلق
حجم التداول
13,366
الربح لكل سهم
0
العائد الربحي
-
P/E
-1
حجم السوق
120,743,436
أصول ذات صلة
C
CRSP
-1.550
(-4.53%)
32.650 USD
E
EDIT
-0.07000
(-5.88%)
1.12000 USD
N
NTLA
-0.42000
(-5.75%)
6.88500 USD
S
SGMO
-0.03190
(-4.89%)
0.62010 USD
V
VCEL
-0.920
(-2.07%)
43.470 USD
المزيد
الأخبار المقالات

العنوان: Seres Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by thecompany are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.